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 1 
RNA AND THERAPEUTIC MODES 
 
Sidney Altman  
Yale University, Department of Molecular, Cellular and Developmental 
Biology, New Haven, CT, 06520 
 
RNA plays a central role in biology. Its primacy, and variety of sizes in 
vivo, indicates that it may be useful as a target and a means of developing a 
therapeutic tool. Some of these problems involve extensive and detailed 
analysis of metabolic pathways in vivo, which is a classic tool for drug 
development, and others are centered on a simple analysis of a particular 
situation and how to deal with the RNAs involved. The size of RNA and its 
negative charge present problems in targeting diseased cells in this regard. 
However, different ways of approaching all these issues are available. These 
aspects of developing a clinical tool will be discussed. 
 2 
ANTISENSE OLIGONUCLEOTIDES TO INDUCE EXON 51 SKIPPING 
IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY: WHAT WE 
ARE LEARNING FROM CLINICAL TRIALS 
 
Francesco Muntoni  
 
UCL Institute of Child Health, The Dubowitz Neuromuscular Centre, 30 
Guilford Street, London, WC1N 1EH, United Kingdom 
 
The UK MDEX Consortium (http://www.mdex.org.uk/) has been involved 
since 2005 in preclinical studies and in clinical trials using antisense 
oligonucleotides to induce exon skipping in boys with Duchenne muscular 
dystrophy (DMD). In close collaboration with AVI Biopharma, in 2008 we 
completed a two doses-escalation study of a morpholino oligonucleotide 
(AVI-4658) which induces skipping exon 51 in dystrophin mRNA in seven 
patients with DMD. In 2009 we have started and now almost completed, 
also in close collaboration with AVI Biopharma, an open label, dose 
escalation study in ambulant DMD boys aged 5-15 years with deletions that 
benefit from skipping exon 51. This study consists of 12 weekly 
administrations of AVI-4658 followed by a muscle biopsy to assess 
dystrophin expression at baseline and 14 weeks. 
During the last few years we have optimised methodologies for the 
identification of lead antisense compounds; we have elected to skip exon 51 
based on our experience of the mild resulting in-frame mutations; we have 
developed techniques to detect and quantitate small changes in dystrophin 
protein expression, and of its associated protein partners in the dystrophin 
glycoprotein complex.  
The encouraging results of the previous IM study, and the interim analysis 
of the ongoing systemic IV study, together with the excellent tolerability 
profile of the morpholino antisense oligonucleotides, clearly suggest that 
this approach has the potential to lead to the development of a drug that 
could play a role in the treatment of DMD. 
A number of challenges remain, ranging from the optimal administration 
regimens of the antisense oligonucleotides, to the initiation of studies 
targeting other exons, to the validation and adoption by the international 
scientific community of clinical and biochemical outcome measures which 
could allow to compare and learn from the different studies which are being 
planned or executed, to the regulatory complexity of antisense 
oligonucleotides as indeed the level of personalised approach that these 
compounds bring is currently without precedent for a genetic disease. 
In my presentation will discuss what we have learned since 2005 in 
relations to these various issues and how this is informing our future 
approach to exon skipping in DMD. 
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THE DEVELOPMENT OF RNA-MODULATING THERAPIES 
 
Judith C.T. van Deutekom  
Prosensa Therapeutics BV, VP Discovery Leiden, 2300, Netherlands 
 
RNA-modulating therapeutics like antisense oligonucleotides (AONs) 
provide an innovative tool for targeted modulation of gene expression 
and/or to correct mutated mRNA causing life threatening disorders. An 
increasing number of studies show that AONs can interfere with splicing in 
order to induce exon skipping, enhance exon inclusion, or correct splicing 
mutations, can remove mutant RNA or protein domains, or block RNA 
expression. Prosensa Therapeutics applies the AON technology platform to 
develop RNA-modulating therapies for a variety of genetic diseases, 
including neuromuscular and neurodegenerative disorders such as 
Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1), 
Huntington's Disease (HD) and Spinal Muscular Atrophy (SMA). First 
proof-of-concept was recently obtained with PRO051 (GSK2402968) for 
DMD. Based upon promising results from two clinical phase 1/2 studies the 
compound is now moving into phase 3. We will present highlights and 
challenges from our development program. 
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DEVELOPMENT OF UNIVERSAL ANTIDOTES TO CONTROL 
APTAMER ACTIVITY 
 
Bruce A Sullenger, Sabah Oney, Jaewoo Lee  
 
Duke University Medical Center, Surgery, Box 103035 DUMC, Durham, 
NC, 27517 
 
With an ever-increasing number of people taking numerous medications, 
the need to safely administer drugs and limit unintended side effects has 
never been greater. Antidote control remains the most direct means to 
counteract acute side effects of drugs but unfortunately it has been 
challenging and cost prohibitive to generate antidotes for most therapeutic 
agents. We will describe the development of a set of antidote molecules that 
are capable of counteracting the effects of an entire class of therapeutic 
agents, aptamers. These universal antidotes exploit the fact that when 
systemically administered, aptamers are the only free extracellular 
oligonucleotides naturally found in circulation. We demonstrate that protein 
and polymer-based molecules that capture oligonucleotides can reverse the 
activity of several aptamers in vitro and counteract aptamer activity in vivo. 
The availability of universal antidotes to control the activity of any aptamer 
suggests that aptamers may be a particularly safe class of therapeutics. 
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RNA OLIGONUCLEOTIDES AS REGULATABLE 
ANTITHROMBOTIC AGENTS  
 
 
Richard C Becker1, Christopher Rusconi2, Bruce Sullenger1  
 
1Duke Translational Research Institute, Dept of Medicine, 2400 Pratt Street, 
Durham, NC, 27705, 2Regado Biosciences, Regado Biosciences, 318 
blackwell street, Durham, NC, 27701, 3Duke Translational Research 
Institute, Dept of Medicine, 2400 Pratt Street, Durham, NC, 27706 
 
αThrombosis serves as focal point of interface for tissue injury, 
inflammation and immunity, and represents a unifying phenotype for both 
inherited and acquired disorders of impaired vascular homeostasis. Actively 
controlled and fully reversible antithrombotics potentially expand the 
current therapeutic paradigm for clinicians, providing flexibility and both 
patient- and condition-specific treatment options. Aptamers are single-
stranded nucleic acids that bind with high affinity and specificity to a target 
protein or small molecule. A complementary oligonucleotide, directed to a 
portion of the aptamer can elicit a structural change, preventing an 
interaction and reversing the drugs' pharmacodynamic activity. A family of 
coagulation factor IXa aptamers was identified using iterative in vitro 
techniques (SELEX) against a library of 1014 nucleic acid sequences. The 
lead compound, RB006 and its complementary active reversal agent, 
RB007( figure ) have undergone extensive pre-clinical and clinical testing, 
to include first-in-human phase 1a, b and c studies, a phase 2A pilot study 
and an ongoing, international phase 2B investigation of patients with an 
acute coronary syndrome undergoing percutaneous coronary intervention.  
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DELIVERING ON THE PROMISE OF RNA THERAPEUTICS 
 
Henrik Ørum  
Santaris Pharma A/S, Hoersholm, 2970, Denmark 
 
Short, high affinity oligonucleotides based on the LNA chemistry are able 
to potently and specifically inhibit mRNA and miRNA in-vitro and in in-
vivo. Target inhibition can be achieved in many different tissues upon 
systemic delivery and can be sustained by very infrequent dosing. Notably, 
short LNA oligonucleotides do not require any form of delivery vehicle to 
exert their potent pharmacology in cell cultures or experimental animals. To 
date, four LNA oligonucleotides have advanced to clinical trials in cancer 
and infectious diseases. The most advanced compound, SPC3649, targets 
miRNA-122 and is being developed for the treatment of HCV. The 
presentation will provide an overview of the LNA technology platform and 
the clinical candidates, with particular emphasis on SPC3649. 
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SMALL RNA BASED THERAPIES FOR THE TREATMENT OF HIV 
INFECTION 
 
John J Rossi  
 
Beckman Research Institute of the City of Hope, Molecular and Cellular 
Biology, 1450 E. Duarte Rd., Duarte, CA, 91010 
 
Despite the widespread use of chemotherapy for the treatment of HIV 
infection there still exists a need for new approaches for treatment of HIV 
infection due to viral drug resistance and toxicity problems. To address 
these problems we have developed and tested a novel combination of small 
RNA based inhibitors which inhibit the virus as well as cellular transcripts. 
One approach involves the use of small Pol III expression cassettes in a 
gene therapy stem cell setting. The inhibitory RNAs consist of an RNAi 
triggering anti-HIV shRNA, a hammerhead ribozyme targeting a cellular 
co-receptor and a nucleolar localizing TAR decoy. This triple combination 
is currently in a first in man clinical trial for AIDS/lymphoma patients using 
gene modified autologous hematopoietic stem cells in a stem cell transplant 
setting. The background and current status of this trial will be discussed. 
The second approach involves synthetic anti-HIV envelope aptamer-siRNA 
combinations which have a dual inhibitory function. The aptamer 
neutralizes free virus, but also serves as a vehicle for delivery of anti-HIV 
and cellular targeted Dicer substrate siRNAs into HIV infected cells. These 
novel inhibitors have been tested in a humanized mouse model for their 
ability to inhibit HIV replication and spread. The animals were first 
challenged with HIV followed several weeks later by intravenous injection 
of the aptamer-siRNA chimeras. Remarkably this dual inhibitory approach 
resulted in up to 1 million fold inhibition of viral replication after the first 
administration. More importantly, the dual inhibitors resulted in complete 
protection from T-cell depletion well beyond the last injection. This is in 
contrast to the untreated animals and controls which suffered substantial 
CD4 Tcell depletion. These results will be discussed in the context of 
possible use in humans. 
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PREVENTION OF EXPERIMENTAL AUTOIMMUNE 
ENCEPHALOMYELITIS IN MICE USING AN ANTI-IL-12/23 
NUCLEIC ACID APTAMER 
 
P. Shannon Pendergrast, Robert Silva, Alicia Ferguson, Kristin Thompson, 
Ryan Boomer, Joe Fraone, Paul Hatala, Jason Killough, Sharon Cload, 
Karen Olsen  
 
Archemix Corp, Discovery Biology, 300 Third St., Cambridge, MA, 02139 
 
Nucleic acid aptamers, short oligonucleotides which fold into well-defined 
three-dimensional structures capable of specifically binding proteins, have 
emerged as a new class of therapeutic compounds. While numerous 
aptamers have been shown to inhibit a variety of targets, no systemically 
administered aptamer has shown efficacy in an inflammatory disease 
model. IL-23 is a critical cytokine for the development of mouse 
experimental autoimmune encephalomyelitis (EAE), a model for multiple 
sclerosis characterized by immune inflammation of the CNS. It is a 
heterodimeric protein, and antibodies specific for either the p40 or the p19 
sub-units protect mice from EAE. A non-vascular site of action for IL-23 in 
EAE is supported by expression data and the observation that EAE 
induction is rescued in IL-23 knock-out mice by ectopic expression of IL-23 
in the CNS but not in the vascular compartment. We have generated an 
aptamer that inhibits mouse IL-23 and the related cytokine mouse IL-12. 
The aptamer inhibits mIL-23-dependent STAT3 activation of human PHA 
blasts by either mIL-23 or mIL-12 (IC50s for both at ~6nM). More 
importantly, we have found that systemic chronic dosing of our aptamer 
prevents PLP(139-151)-induced EAE in mice. The aptamer reduces 
symptoms of the disease in a dose-dependent manner; with the highest dose 
(50 mg/kg) completely preventing the onset of disease. This is the first 
demonstration of efficacy by a systemically administered aptamer in an 
inflammatory disease model and significantly expands the range of 
indications for this powerful class of therapeutic compounds. 
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CREATING RNA APTAMERS TO MODULATE FUNCTIONS OF 
HUMAN ESTROGEN RECEPTOR ALPHA 
 
Daiying Xu1, Antonis Kourtidis2, Douglas Conklin3, Hua Shi1  
 
1SUNY, University at Albany, Department of Biological Sciences, 1400 
Washington Ave., Albany, NY, 12222, 2Mayo Clinic Cancer Center, Griffin 
Cancer Research Building, 4500 San Pablo Rd., Jacksonville, FL, 32224, 
3Gen*NY*Sis Center for Excellence in Cancer Genomics, University at 
Albany, Department of Biomedical Sciences, 1 Discovery Dr., Rensselaer, 
NY, 12144 
 
A significant number of breast cancers are estrogen receptor (ER)-positive 
and treatable by ER antagonists. The human estrogen receptor (hER) alpha 
protein is composed of multiple domains and bears multiple sites interacting 
with other factors or elements. However, all ER antagonists currently in use 
target the ligand-binding pocket of ER. We hypothesized that some other 
sites on hER alpha may be validated as new drug targets for treating breast 
cancer and other estrogenopathies. To test this hypothesis, we used RNA 
aptamers as a means for modulation of hER alpha functions through 
specific protein surface occlusion.  
 
Two classes of high affinity RNA aptamers have been developed for 
unliganded full length hER alpha through the method of in vitro selection. 
Class I aptamers bind to both isoforms of hER, alpha and beta, with similar 
affinities, while class II aptamer only binds to hER alpha with high affinity. 
These results suggested that the two classes bind to different sites on hER 
alpha. To study the efficacy of the aptamers in breast cancer cell lines, 
genetic systems have been constructed to produce aptamers through 
transcription from synthetic genes delivered into the cells. In ER-positive 
breast cancer cell line MCF 7, the expressed aptamers reduced hER alpha-
driven luciferase gene activity by 30-50%. 
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PRECLINICAL DEVELOPMENT OF OSTEOPONTIN APTAMER AS 
ADJUVANT THERAPY FOR METASTATIC BREAST CANCER 
 
Zhiyong Mi1, Virginia Burns2, William Zamboni3, Paul Kuo1  
 
1Duke School of Medicine, Department of Surgery-General, Box 3522 Med 
Ctr, Durham, NC, 27710, 2Duke Translational Medicine Institute, Duke 
Translational Research Institute, Box 3850 DUMC, Durham, NC, 27705, 
3UNC CH School of Pharmacy, Pharmacotherapy and Experimental 
Therapeutics, 1013 Genetic Medicine Building, Chapel Hill, NC, 27599 
 
Breast cancer remains one of the most common and devastating 
malignancies worldwide. Clinically, over 95% of women with breast cancer 
have no overt metastatic disease at initial diagnosis, yet half of these women 
will eventually die from breast cancer metastasis in the absence of systemic 
therapy. Osteopontin (OPN) is a secreted tumor protein which is recognized 
as a mediator of breast cancer growth and metastasis, thus it represents an 
attractive therapeutic target for RNA aptamer-based therapy. An RNA 
aptamer (OPN-R3) directed against OPN has been identified using SELEX. 
This aptamer has shown to significantly decrease local progression and 
metastases in a xenograft model of human breast cancer through ablation of 
OPN surface. Preliminary evidence indicated that OPN-R3 had a high 
potential for translational impact and further Preclinical studies have been 
initiated to translate this innovative therapy into clinical trials. Thus far, the 
team has successfully completed: (1) Optimization studies of the OPN-R3 
aptamer for increased biostability (2) In vitro and In vivo studies to evaluate 
Kd and t1/2 for the optimized OPN-R3 aptamer, (3) Evaluation of various 
dosing strategies, (4) Confirmation of aptamer function through further 
efficacy studies using Murine xenograft models (MDA-MB231 human 
breast cancer cells). Herein we discuss the current results from these studies 
and how the data will fuel the next phase of preclinical development for this 
innovative breast cancer therapeutic.  
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MODELLING AND GENE SILENCING IN SPINOCEREBELLAR 
ATAXIA TYPE 7  
 
Sandro Alves,1 Morwena Latouche1, Sandra Duqué2,3, Thibaut Marais2,3, 
Alice Chort1, Alexis Brice1, Giovanni Stevanin1, Martine Barkats2,3, Annie 
Sittler1,2  
 
1UPMC/Univ. Paris 6, Inserm UMRS 975, CNRS 7225, Centre de 
Recherche - Institut du Cerveau et de la Moelle, Paris, France. 2CNRS FRE 
3087-GENETHON, Evry, France. 3Institut de Myologie, UMR974 
INSERM-UPMC-CNRS-AIM, Paris, France  
 
Spinocerebellar ataxia type 7 is a dominantly inherited neurodegenerative 
disorder. The mutation has been identified as a CAG trinucleotide repeat 
expansion in the coding region of the ATXN7 gene which encodes the 
ataxin-7 protein (ATXN7). In the present work we engineered lentiviral 
vectors encoding either truncated wild-type and truncated mutant human 
ataxin-7 to develop an SCA7 in vivo model. In this study, we demonstrate 
that overexpression in the cerebellum of adult mice of mutant but not wild-
type human ataxin-7 is associated with the formation of ubiquitinated 
ataxin-7 aggregates, loss of the calbindin and parvalbumin markers, 
disruption of the neurofilaments and microtubule-associated protein type 2, 
and strong activation of astrocytes, suggesting neuronal dysfunction.  
Gene silencing by RNA interference (RNAi) is a process that suppresses the 
expression of a gene at the RNA level. RNAi holds promise as a potential 
therapy to treat dominantly inherited human diseases, many of which are 
currently untreatable, such as SCA7. Thus, miRNA-based approaches may 
provide more appropriate biological tools for expressing inhibitory RNAs in 
the brain, the implications of which are crucial to the development of RNAi 
for therapeutic applications. In the present work, we engineered lentiviral 
vectors encoding a microRNAs (miRNA) cassette targeting human ATXN7. 
The efficacy of these miRNAs was assessed by co-transfecting human 293T 
cells with plasmids expressing truncated wild-type or truncated mutant 
human ATXN7 (trATXN7-10Q or trATXN7-100Q) with the miRNAs 
vectors and analyzed by immonufluorescence, western-blot and RT-PCR.  
We are currently testing these miRNAs in the lentiviral-based mouse model 
of SCA7 in order to check if we obtain a reduction in the SCA7 
neuropathological readouts of neurotoxicity.  
 12 
RNA APTAMERS TARGETING THE RECEPTOR-BINDING DOMAIN 
OF THE CANCER- ASSOCIATED PROTEASE UROKINASE 
PLASMINOGEN ACTIVATOR 
 
Lisbeth M Andersen, Daniel M Dupont, Jeppe B Madsen, Jørgen Kjems, 
Peter A Andreasen  
 
Aarhus University, Department of Molecular Biology, Gustav Wieds Vej 
10C, bygn. 1.3, Aarhus C, 8000, Denmark 
 
Systematic evolution of ligands by exponential enrichment (SELEX) is a 
relatively new approach for generating potential therapeutic and diagnostic 
agents. The technique combines the ability of RNA or DNA 
oligonucleotides to fold into a variety of three-dimensional structures, with 
the possibility of selecting, from very large pools of random sequences 
(~1015), the ones capable of binding to a target of interest. We have 
generated a library of serum-stable 2´-F-pyrimidine modified RNA 
oligonucletides and used it in a SELEX experiment to select sequences, or 
so-called aptamers, binding to human urokinase plasminogen activator 
(uPA). The aptamers have been analysed by surface plasmon resonance 
(SPR) and bind to the amino terminal fragment of human but not murine 
uPA, with KD-values in the low nanomolar range. SPR analyses and cell 
assays have shown that aptamer binding block the association of uPA with 
its receptor uPAR and in consistency with the probable binding area, they 
do not inhibit the uPA proteolytic activity directly. However, the aptamers 
inhibit cell-dependent plasminogen activation. uPA-binding aptamers 
represent a promising principle for interfering with the pathophysiological 
functions of the plasminogen activation system and targeting the receptor-
ligand interaction through uPA may be beneficial as uPAR-directed agents 
may not be antagonists of all functions of uPAR.  
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REGULATION OF STAT3 ALTERNATIVE SPLICING AND ITS ANTI-
TUMORIGENIC POTENTIAL 
 
Francesca Zammarchi, Luca Cartegni  
 
Memorial Sloan-Kettering Cancer Center, Memorial Pharmacology and 
Chemistry, 1275 York Avenue, New York, NY, 10021 
 
Signal transducer and activator of transcription (STAT) proteins are a 
family of signalling molecules implicated in growth factors and cytokines 
signalling. STATs are latent transcription factors thatare sequestered in the 
cytoplasm in an inactive form. Upon JAK/SRC dependent phosphorylation, 
they dimerize, translocate to the nucleus, and activate transcription of target 
genes. In normal physiological conditions, STAT proteins have a limited 
activation period, whereas they (especially STAT3) show a persistent 
activation in many human cancers. This promotes growth and survival of 
tumor cells, induces tumor angiogenesis and suppresses anti-tumor immune 
responses. 
 
Because of its pivotal position at the convergence of many oncogenic 
tyrosin-kinase signaling pathways, STAT3 seems to be particularly suitable 
as a molecular target for cancer therapy, especially considering that tumor 
cells tend to become addicted to persistent STAT3 signaling. 
 
A naturally occurring alternative splicing variant, STAT3-beta, uses an 
alternative acceptor site within exon 23 and leads to the production of a 
truncated isoform, which lacks the C-terminal trans-activation domain 
(TAD). STAT3-beta can act as a dominant negative regulator of 
transcription and promote apoptosis. 
 
We are characterizing the cis-elements and trans-acting factors that regulate 
STAT3 exon 23 alternative splicing and have used modified antisense 
oligonucleotides to specifically induce a shift from the abundant, active 
STAT3-alpha to the anti-tumorigenic STAT3-beta isoform.  
 
Induction of the endogenous STAT3-beta leads to cell death and apoptosis 
in cell lines addicted to STAT3 activation and causes tumor regression in 
vivo. 
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FLUORESECENT NANODIAMOND-ASSISTED DELIVERY OF 
DSRNAS 
 
Han-Yi E Chou1, Jia-Ying Lee2  
 
1National Taiwan University, Graduate Institute of Oral Biology, 1 Chang-
Der Street, Taipei, 10002, Taiwan, 2National Taiwan University, Graduate 
Institute of Oral Biology, 1 Chang-Der Street, Taipei, 10002, Taiwan 
 
The incorporation of targeting, imaging, and ablation/therapeutic 
capabilities on a biocompatible RNA delivery platform is a powerful 
approach for cancer therapy. Matching these multiple requirements, type Ib 
fluorescent nanodiamonds (FNDs) can emit no photobleaching and no 
photoblinking fluorescence from their nitrogen-vacancy point defects, at a 
spectral range well suited for long term observation in living cells. Here we 
report that FNDs can assist delivery of siRNAs, resulting in enhanced 
efficacy of gene silencing at very low dose of siRNA. This is achieved via 
caveolin-mediated endocytosis of FND-siRNA particles, which are rapidly 
released from endosome compartments as shown by electron microspe 
studies. Time-dependent studies also indicate that the siRNA delivered 
attain target gene silencing in a more rapid, as well as prolong kinetics than 
conventional delivery systems. Moreover, long-term presence of FNDs do 
not show detectable impact on cell viability and proliferation, while 
providing excellent indication for positive delivery and cell tracing. The 
possible mechanisms involved are discussed. 
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BINDING, STABILIZATION, AND DELIVERY OF THERAPEUTIC 
RNA 
 
Lisa Cillessen1, Matthew Warner1, Stephanie Barber1, Brooke Parker1, 
Jenna McNew1, Adam Wanekaya2, Kartik Ghosh3, Lifeng Dong3, Michael 
Craig1, Richard Garrad1, Garry Glaspell4, Robert DeLong1 
 
1Missouri State University, Department of Biomedical Sciences, 901 S. 
National, Springfield, MO, 65897, 2Missouri State University, Department 
of Chemistry, 901 S. National, Springfield, MO, 65897, 3Missouri State 
University, Department of Physics, Astronomy, and Materials Science, 901 
S. National, Springfield, MO, 65897, 4 Virginia Commonwealth University, 
Department of Chemistry, 810 Cathedral Place, Richmond, VA, 23284 
 
Our current group focus is on the binding, stabilization, and delivery of 
therapeutic RNA via nanomaterials. We have synthesized gold, manganese 
and zinc oxide nanoparticles by chemical and physical methods and 
characterized their interaction with RNA. Using UV/Vis and dynamic laser 
light spectroscopic measurements we have been able to determine 
association of the RNA to the Au, MnO and ZnO nanoparticles. Absorbance 
differences and shifts in the nucleic acid or nanomaterial spectra reveal 
these interactions. A measurable change in surface or zeta potential is 
observed upon their association as well. The therapeutic utility and 
pharmacologic potential of macromolecular RNA in particular is greatly 
limited by its instability as it is subject to rapid chemical and enzymatic 
degradation. Therefore, one must focus on the stabilization of RNA before 
imagining delivery. Thus recently we have begun experiments aimed at 
determining the nanomaterials ability to stabilize RNA when subjected to 
such accelerated degradation treatment. The kinetics and extent of 
degradation are monitored by electrophoretic and HPLC determination and 
thus protection of the RNA by binding to biomaterials and nanoparticles can 
be measured. Protection against chemical, RNase, and nucleases present in 
serum and various tissue extracts is sought. Once a stabilizing condition for 
the RNA bionanoparticles is devised, one can begin to envision the delivery 
of splice-site switching oligonucleotide or siRNA against model or 
therapeutic RNA targets. 
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EFFICIENT SIRNA DELIVERY INTO PRIMARY CELLS BY A 
PEPTIDE TRANSDUCTION DOMAIN-DSRNA BINDING DOMAIN 
FUSION PROTEINS 
 
Akiko Eguchi1,2, Hiroyuki Michiue1,2, Yung-Chi Chang3, Bryan R Meade1,2, 
Craig T Fredrickson2, Karl Willert2, Nitin Puri4, Steven F Dowdy1,2  
 
1HHMI, Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy 
chase, MD, 20815, 2UCSD, Department of Cellular & Molecular Medicine, 
9500 Gilman Drive, #0686, La Jolla, CA, 92093-0686, 3UCSD, Department 
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92096, 4 Ambion, Applied Biosystems, Life Technologies, 2130 Woodward 
St, Austin, TX, 78744 
 
Targeted mRNA degradation by siRNA-induced RNA interference (RNAi) 
allows for selective manipulation of cellular phenotypes and has great 
potential to treat human disease. However, due to their size (~14,000 
Dalton) and charge, siRNAs have no bioavailability to enter unperturbed 
cells. Moreover, current delivery approaches fail to deliver siRNAs into the 
cast majority of cell types, especially primary cells. Here we report a siRNA 
delivery approach that targets 100% of cells by Peptide Transduction 
Domain-dsRNA Binding Domain (PTD-DRBD) fusion proteins. DRBDs 
bind siRNAs in a sequence-independent manner that masks the negative 
charge, allowing for cationic PTD-mediated siRNA delivery. PTD-DRBD 
delivered siRNAs induced RNAi responses in the entire population of all 23 
cell types tested, including primary human umbilical vein endothelial cells 
(HUVEC), primary fibroblasts, keratinocytes, primary T cell, macrophage 
and human embryonic stem cells (hESCs). Indeed, PTD-DRBD-siRNA 
mediated knockdown of the Oct4 pluripotent transcription factor induced 
hESC differentiation. Moreover, we observed no cytotoxicity, minimal off-
target transcriptional changes and no induction of innate immune responses. 
Using transgenic ROSA26 mice expressing luciferase in the nasal and 
tracheal passages, we showed that PTD-DRBD–delivered Luc siRNA led to 
an extensive reduction of luciferase expression throughout the nasal and 
tracheal passages. In addition, PTD-DRBD delivered EGFRvIII siRNAs 
resulted in EGF Receptor knockdown in intracerebral glioblastoma tumors 
in vivo. PTD-DRBD combinatorial delivery of EGFR and Akt2 siRNAs 
synergized to dramatically increase survival and decrease tumor volume in 
pre-clinical models of glioblastoma. Taken together, these observations 
demonstrate a near ubiquitous siRNA delivery approach that has the 
potential to perform RNAi manipulation on currently difficult cell types for 
screening and in vivo therapeutic applications. 
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SYNTHESIS OF THE RNA ANALOG 2’-O-METHYL-3’-AMINO-3’-
DEOXYRIBONUCLEIC ACID 
 
Benjamin D Heuberger1,2,3, Jack W Szostak1,2,3  
 
1Howard Hughes Medical Institute, Molecular Biology and Center for 
Computational and Integrative Biology, 7215 Simches Research Center, 
Boston, MA, 02114, 2Massachusetts General Hospital, Molecular Biology 
and Center for Computational and Integrative Biology, 185 Cambridge 
Street, Boston, MA, 02114, 3Harvard Medical School, Genetics, 185 
Cambridge Street, Boston, MA, 02114 
 
The synthesis of 2’-O-methyl-3’-amino-3’-deoxyuridine is described. This 
RNA analog formally derives from the combination of previously separate 
RNA modifications known individually to enhance the thermal stability of a 
standard Watson-Crick double helix. The novel polymer may enjoy an 
enhanced level of known advantages imparted by the individual 
modifications – those primarily being nuclease resistance and thermal 
stability. Initial nonenzymatic primer extension experiments indicate ready 
compatibility with RNA as evidenced by efficient templated 
oligomerization. Future experiments assessing its potential, as an antisense 
therapeutic candidate will be pursued. 
 18 
OVERCOMING IMMUNOSTIMULATORY ISSUES ASSOCIATED 
WITH THERAPEUTIC SIRNA FOR TOPICAL DELIVERY TO THE 
LUNG  
 
Stephen A Hughes1, Kenneth L Clark1, Jill Coates1, Doug I Ball1, Kitty E 
Moores1, Joel D Parry2, Steffanos I Ioannidis1, Paul A Wilson3, Mark R 
Edbrooke1  
 
1GlaxoSmithKline, Respiratory CEDD, Gunnels Wood Road, Stevenage, 
SG1 2NY, United Kingdom, 2GlaxoSmithKline, Safety Assessment, Park 
Road, Ware, SG12NY, United Kingdom, 3GlaxoSmithKline, Computational 
Biology, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom 
 
The Immunostimulatory side effects of siRNAs must be taken into account 
when considering the application of siRNAs for therapeutic applications. 
Toll-like receptors (TLR3, TLR7, TLR8 and TLR9) can recognise siRNA 
leading to immune activation. This immune activation by siRNAs can be 
abrogated by the careful selection and screening of siRNA sequences. In 
order to circumvent any downstream developability issues we have 
established a methodology for screening out any potential 
immunostimulatory activity using a combination of bioinformatic, in vitro 
and in vivo studies in rodents. This methodology will be presented together 
with data for both nasal and pulmonary targets showing that siRNAs can be 
well tolerated in vitro and when delivered topically to the airways in vivo. 
The implications of this data for the development of siRNAs for other nasal 
and pulmonary targets will be discussed 
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EFFECTIVE INHIBITION OF CORE GENE OF HCV 3A GENOTYPE 
USING SYNTHETIC AND VECTOR DERIVED SIRNAS 
 
Saba Khaliq, Shah Jahan, Bushra Ijaz, Sajida Hassan  
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HCV has been considered a significant risk factor in HCV induced liver 
diseases and development of hepatocellular carcinoma, with genotype 3a 
responsible for most of the cases in Pakistan. Current combination treatment 
of interferon-α and ribavirin has shown limited efficiency, poor tolerability 
and significant expense so alternative options are desperately needed. RNA 
interference (RNAi) is a novel regulatory and powerful silencing approach 
for molecular therapeutics through a sequence-specific RNA degradation 
process to inhibit virus infection or replication. Core gene of HCV comes in 
immediate contact with cells during infection and play complex roles in 
regulation of cells growth and host genes expression essential for 
infectivity. Therefore, Core gene of HCV might be a relevant target for new 
drug development. In the present study, full-length HCV Core gene of 
Pakistani HCV-3a isolates were amplified and sequenced from serum 
samples as there was previously no available sequence of the local HCV-3a 
genotype. For in vitro analysis, mammalian expression plasmids expressing 
HCV-3a Core gene was constructed by insertion of amplified gene into 
pCR3.1/FlagTAG. The focus was on inhibition of HCV by using consensus 
small interfering RNAs (siRNAs) against HCV-3a genotype which were 
designed and constructed. The activity of HCV-specific siRNAs were 
determined through co-transfection with mammalian expression vectors of 
HCV-3a into Huh-7 cells. The expression of Core gene was dramatically 
reduced both at mRNA and protein levels as compared with Mock 
transfected and control siRNAs treated cells in a dose dependent manner. 
The potential of siRNAs specificity to inhibit HCV 3a replication in serum-
infected Huh-7 cells followed by a combined treatment of effective siRNAs 
for counteracting viral escape by mutation variants and a significant 
decrease in HCV viral copy number and protein expression was observed. 
For long lasting effect of siRNAs, vector based siRNAs (shRNAs) were 
designed and tested against HCV-3a Core (most effective siRNAs) which 
resulted in a similar pattern of inhibition on RNA and protein expression of 
HCV Core as synthetic siRNAs. Moreover, to evaluate the efficacy of 
shRNA against the whole virus, the cell culture tested shRNA were tested 
for inhibition of HCV replication and found to be equally effective like 
siRNAs using HCV-3a serum infected Huh-7 cells. This proof-of-principle 
study clearly demonstrates that the RNAi-mediated silencing of HCV Core 
resulting from mRNA degradation be among the first of their type for the 
development of effective siRNA based therapeutic opportunities against 
HCV-3a genotype. 
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IL-23 is a heterodimeric cytokine consisting of the p40 subunit of IL-12 and 
a unique p19 subunit. IL-23 binds to activated T and NK cells via a distinct 
receptor from IL-12 and has distinct affects, including the stimulation of IL-
17. Studies using knock-out mice indicate that IL-23 rather than IL-12 is the 
more relevant cytokine for mouse models of multiple sclerosis, rheumatoid 
arthritis, and IBD. We have used SELEX™ (Systematic Evolution of 
Ligands by Exponential enrichment) to generate nucleic acid aptamers to 
IL-23. Several selections yielded a family of aptamers that bind with low 
nanomolar affinity and demonstrate selectivity for IL-23 over IL-12. 
Isolation and optimization of the core family sequence produced a 34 
nucleotide derivative, ARCX, with a G-quartet structure and subnanomolar 
affinity for IL-23. PEGylation of ARCX generated ARCY, which is capable 
of completely inhibiting IL-23-dependent activation of the STAT3 signal 
transduction pathway of T-cells in vitro (IC50 = 1.5 nM). Furthermore, 
ARCY completely inhibits IL-23-dependent IFN-γ and IL-17a release from 
immune cells with low nanomolar IC50s. However, ARCY inhibits IL-12-
dependent IFN-γ release to a much less extent; with IC50 > 50X higher than 
for IL-23 and only 60% inhibition at 1 uM. This aptamer is an intriguing 
lead for the development of novel IL-23 specific anti-inflammatory agents 
for in vitro studies and possible therapeutic purposes. 
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MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression 
in all multicellular organisms. These tiny ~20 nt RNAs regulate the majority 
of physiological processes and the deregulation of miRNA expression is a 
hallmark of many diseases. Therefore, many efforts are being made to 
develop new, more sensitive methods of miRNA analysis and improve the 
existing methods to make miRNA characteristics more accurate. The most 
standardized and widely used method is Northern blot hybridisation which 
is considered the “gold-standard” in miRNA detection. However, all 
Northern blot protocols are aimed at enhancing the sensitivity of the method 
rather than at increasing the signal resolution. These protocols are focused 
on miRNAs leaving many questions regarding effective pre-miRNA 
detection unanswered. Our protocol fulfils this gap and provides a detailed 
methodology for the robust detection of both miRNAs and pre-miRNAs. 
We show how to perform the Northern blot analysis of miRNAs and their 
precursors with a single-nucleotide resolution allowing us to detect 
individual length variants and to evaluate their relative quantities in cells. 
Our protocol is applicable for all analyses of any kind of endogenous and 
exogenous RNAs, falling within 20-30 nt and 50-80 nt length ranges, 
corresponding to the miRNA and pre-miRNA lengths respectively. We 
discuss all steps of the procedure from the perspective of the enhanced 
resolution of short RNAs and suggest its possible applications. We 
demonstrate how to use high-resolution Northern blot in the investigation of 
miRNAs biogenesis and function, as well as in the diverse applications of 
RNAi and miRNA technologies, when the molecular size of reagents 
released from vectors needs to be precisely defined. Specifically, using the 
protocol we show how to evaluate the precision of Drosha and Dicer 
cleaveages and how to determine the processing of short hairpin RNA 
constructs (shRNAs) composed of CNG repeats. 
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Gastrin-Releasing Peptide Receptor (GRPR) had a long and successful 
history being utilized for receptor-mediated delivery of cytotoxins, 
immunotoxins, and radioactive compounds, and this study was intended to 
extend it into delivery of oligonucleotides. A 2'-O-Me phosphorothioate 
antisense oligonucleotide (termed 623), which corrects abnormal splicing 
when delivered into nucleus, was conjugated to a bombesin (BBN) peptide 
at its 5'-end. Intracellular delivery of oligonucleotides was tested in GRPR 
expressing PC3 cells which had been stably transfected with a reporter 
comprised of the firefly luciferase gene interrupted by an abnormally 
spliced intron. The BBN-623 conjugate produced significant higher 
luciferase expression compared to the ‘free’ 623, and this increase was 
reversed in the present of excess amount of free BBN peptide. The BBN-
623 conjugate produced a gradual increase followed by a gradual decline, 
while the cationic lipid-623 complex caused a rapid increase followed by a 
monotonic decline. Dose-dependent uptake study revealed a combination of 
a saturable, receptor-mediated endocytosis and non-saturable pinocytosis 
for uptake of BBN-623 in PC3 cells. In addition, the Km value for satuable 
uptake of the conjugate was compared favorably to the EC50 value for the 
pharmacological response, which indicated that the saturable, receptor-
mediated endocytosis mainly contributes to the effectiveness of the 
conjugate. Effects of selective endocytosis inhibitors, and of transfection 
with a dominant-negative mutant dynamin, on cellular uptake showed that 
BBN-623 utilized a clathrin-dependent, actin-dependent, and dynamin-
dependent pathway to enter PC3 cells. The subcellular distribution of the 
BBN-623 conjugate was partially co-localized with a marker for clathrin. 
Membrane vesicles containing BBN-623 were colocalized with those 
marked by transiently expressed GFP chimeras of Rab7 and Rab9, 
demonstrating that BBN-623 was transported to late endosomes and then 
the trans-Golgi network. These observations suggest that the BBN peptide-
oligonucleotide conjugate enters cells via a process of receptor-mediated 
endocytosis mediated by GRPR. 
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Sigma receptor is a membrane protein that is over-expressed in some cancer 
cells such as prostate, lung and breast tumor cells.1 Several small molecules 
including anisamide, haloperidol, SA4503 and opipramol have been 
reported as high affinity sigma-receptor ligands. Recently, it was reported 
that anisamide targeted liposomes effectively delivered cargos to sigma 
receptor-expressing tumor cells.2,3 Herein, we report the synthesis and 
evaluation of novel mono- and multi-valent anisamide-oligonucleotide 
(ON) conjugates. Anisamide was effectively converted to a 
phosphoramidite precursor that can be directly introduced into solid phase 
ON synthesis. Using the phosphoramidite, mono- and tri-valent anisamide 
conjugates were synthesized in satisfying yields. The mono-anisamide was 
directly conjugated to the 5’-terminal of the ON, while the tri-anisamide 
was introduced using a three-branched linker. To evaluate biological 
function, we utilized a reporter system wherein effective delivery of a 
splice-switching antisense oligonucleotide (SSO) to the nucleus results in 
up-regulation of luciferase expression. Cellular uptake of unconjugated SSO 
or anisamide conjugates were evaluated in sigma-receptor expressing 
human lung carcinoma H460 cells. The mono-anisamide conjugate showed 
slightly higher uptake compared to the unconjugated SSO, while trivalent-
anisamide conjugate showed significantly greater uptake than the 
unconjugated SSO. The trivalent-anisamide conjugate also displayed high 
luciferase expression as compared to the unconjugated or mono-conjugated 
SSO. Thus, we have demonstrated that the multi-valent anisamide 
conjugates enhanced cell uptake and improved biological effects by direct 
mediation of the sigma receptor.  
 
References:  
(1) Maurice, T.; Su, T-P. Pharmacol. Ther. 2009, 124, 195-206.  
(2) Banerjee, R.; Tyagi, P.; Li, S.; Huang, L. Int. J. Cancer 2004, 112, 693-
700.  
(3) Chono, S.; Li, S-D.; Conwell, C. C.; Huang, L. J. Control. Release, 
2008, 131, 64-69.  
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Protein kinase PKR is a key component of innate immunity. It is activated 
by long stretches of dsRNA and functions to inhibit translation initiation. 
Many cellular and viral transcripts contain nucleoside modifications which 
could affect PKR activation. For example, a 5’-triphosphate confers the 
ability of relatively unstructured transcripts to activate PKR. Herein, PKR 
activation by ssRNA and dsRNA containing internal nucleobase, sugar, and 
phosphodiester modifications is analyzed. We find that for 5’-triphosphate-
containing ssRNA, most base and sugar modifications abrogate activation, 
although 2’-fluoro-modified ssRNA does not, indicative of a critical role for 
hydrogen bonding at the ribose sugar. In the case of dsRNA, a more limited 
set of nucleoside modifications affect PKR activation (1-3). Surprisingly, 
GU wobble pairs also largely abrogate dsRNA-mediated activation when 
present at modest levels. In order to understand the biological implications 
of nucleoside modifications on PKR activation, we have extended the study 
to biologically relevant modified cellular tRNAs and less-modified 
mitochondrial tRNAs (mt-tRNA). We find that a T7 transcript of 
unmodified yeast tRNAphe and natively extracted bovine liver mitochondrial 
tRNAs activate PKR, whereas heavily modified native yeast tRNAphe does 
not. Overall, the findings indicate that nucleoside modifications and wobble 
pairing may serve to discriminate self-RNA and pathogenic RNA in innate 
immunity, and also help in designing non-immune stimulated small RNA 
therapeutics.  
 
1. Nallagatla, S. R. et. al. (2007). Science 318, 1455-1458.  
2. Nallagatla, S. R. & Bevilacqua, P. C. (2008). RNA 14, 1201-1213.  
3. Nallagatla, S. R. et. al. (2008). RNA Biol. 5, 140-144  
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For the past 15-20 years, the intracellular delivery and silencing activity of 
oligonucleotideshas been essentially completely dependent on the use of a 
delivery technology (e.g., lipofection). We have developed a method (called 
“gymnosis”) that does not require the use of any transfectionreagent or any 
additives to serum whatsoever, but rather takes advantage of the normal 
growth properties of cells in tissue culture in order to promote productive 
oligonucleotideuptake. This robust method permits the sequence-specific 
silencing of multiple targets in a large number of cell types in tissue culture, 
both at the protein and mRNA level, at concentrations in the low 
micromolarrange. Optimum results were obtained with locked nucleic acid 
(LNA) phosphorothioategap-mers, but other chemical modifications are 
also active. By appropriate manipulation of oligonucleotidedosing, this 
silencing can be continuously maintained with no toxicity for >240 days. 
High levels of oligonucleotidein the cell nucleus is not a requirement for 
gene silencing, contrary to long accepted dogma. In addition, 
gymnoticdelivery can efficiently deliver oligonucleotidesto suspension cells 
that are known to be very difficult to transfect. Finally, the pattern of gene 
silencing of in-vitrogymnotically-delivered oligonucleotidescorrelates 
particularly well with in-vivosilencing. The establishment of this link is of 
particular significance to those in the academic research and drug discovery 
and development communities.  
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Silencing aberrant gene expression through RNA interference is an 
emerging class of medicine for targeting incurable diseases such as cancer. 
Survivin, is a unique member of the inhibitor of apoptosis protein family, 
involved in the control of mitotic progression and inhibition of apoptosis. 
PLK1 is a serine/threonine kinase that plays a central role in cell division 
and cell cycle progression and its up-regulation is positively correlated with 
a cancer phenotype. The selective overexpression of survivin and PLK1 in 
cancerous tissues compared to normal tissues has been associated with 
disease progression and increased resistance to chemotherapy. Successful 
delivery of such siRNAs to their intracellular targets depends on the 
development of efficient systemic delivery systems. MDRNA has 
developed siRNAs targeting survivin and PLK1 that are highly specific and 
efficacious when delivered systemically with our novel Di-Lipo amino-acid 
(DiLA2) based liposomes to both subcutaneous and orthotopically placed 
liver tumors established in immuno-compromised mice. Repeat 
administration of siRNAs in DiLA2 liposomes resulted in significant 
decrease in mRNA expression in the human-derived liver tumors and a 
dramatic reduction in tumor volume. Furthermore, Survivin and PLK1 
siRNAs encapsulated in DiLA2 liposomes delivered locally via intravesical 
instillation in an orthotopic bladder cancer mouse model elicited significant 
downregulation of mRNA expression that correlated with a substantial 
decrease in tumor volume in a dose dependent manner sustained over a 
period of three weeks. We are further screening potential targets that exploit 
multiple pathways leading to cancer phenotypes for enhanced efficacy and 
prolonged therapeutic effect against a variety of cancers.  
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Adenoviral (Ad) vectors have been extensively utilized to target shRNAs to 
cancer cells. These vectors can infect many cell types, both proliferating and 
quiescent, they do not integrate into the host chromosome and are easy to 
construct and grow to high titers. Furthermore, oncolytic Ad vectors armed with 
an shRNA have also recently been constructed. Oncolytic Ad vectors are 
designed to specifically replicate and lyse cancer cells through deletions, 
mutations or additions of genes to the Ad genome. Due to the replication of 
these vectors in cancer cells, shRNAs levels encoded within these vectors 
would increase specifically in these cells. Previous studies have shown that the 
addition of oncogene-targeted shRNAs to oncolytic Ad vectors increased the 
anti-tumour effect of the oncolytic vectors. However, current oncolytic Ad 
vector design include adenoviral genes that code for RNA molecules called 
virus associated RNAs (VA-RNAs). These highly complex RNA structures are 
expressed at high levels during Ad viral replication and are thought to be 
important in inhibiting the intracellular antiviral immunity. Recent studies have 
also found that VA-RNAs are processed into viral miRNAs by the RNAi 
pathway. Due to the high levels of VA-RNA expression, the RNAi pathway 
was found to be saturated, reducing the ability of the key RNAi enzymes to 
process other RNA molecules to si- and miRNAs. These results suggest that the 
activity of shRNAs encoded within oncolytic Ad vectors may be reduced when 
the VA-RNAs are expressed. Therefore, we are currently determining whether 
the levels and activity of shRNAs encoded within oncolytic Ad vectors could be 
increased when the VA-RNAs genes are deleted from the oncolytic Ad genome. 
We have designed breast cancer specific oncolytic Ad vectors encoding a 
luciferase-targeted shRNA with or without the VA-RNA genes. These oncolytic 
Ad vectors were constructed to encode the E1a Ad gene and the luciferase-
targeted shRNA within the same transcript. This large transcript is controlled by 
the breast cancer specific promoter, mammaglobin. The increase in shRNA 
levels will be determined through RNA analysis using northern blots of a panel 
of breast cancer and normal cell lines infected with the oncolytic vectors with or 
without VA-RNA expression. Additionally, increase in shRNA activity will 
also be measured using the luciferase reporter assay system on the infected 
panel of cell lines transiently expressing the luciferase enzyme. Future in vitro 
and in vivo studies with these oncolytic Ad vectors will allow for the 
construction of a potent oncogene-targeted shRNA delivered to breast cancer 
using oncolytic Ad vectors. 
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Transcript profiling and immunohistochemical analysis recently identified 
transmembrane glycoprotein NMB (GPNMB) as a tumor-associated antigen 
overexpressed in glioblastoma multiforme and melanoma cell lines and 
patient tumor samples. Even though the physiological function of GPNMB 
is currently unknown, elevated levels in tumor specimens seem to be a 
valuable prognostic marker and have been correlated with poor prognosis. 
Moreover, its restricted expression in normal tissue makes GPNMB a 
promising candidate for targeted tumor therapy. Therefore our objective is 
to develop high affinity ligands that specifically recognize this receptor and 
to subsequently transform these ligands into anti-tumor therapeutics.  
Starting from a synthetic RNA library, modified with 2´fluoro modified 
pyrimidines for increased nuclease resistance, we selected aptamers that 
bind to recombinant GPNMB protein produced in SF-9 insect cells with 
high affinity. To ensure aptamer binding not only to purified protein in 
vitro, but also to GPNMB in its native cell surface expressed context, 
additional selection rounds were conducted on living cells overexpressing 
GPNMB. After eight rounds of selection, aptamers have been identified 
with binding affinities in the nanomolar range (Kd < 50 nM). Flow 
cytmometry analysis using fluorophore labeled apatmers revealed that 
selected oligonucleotides specifically recognize cells expressing GPNMB 
and are internalized into subcellular compartments, an important 
prerequisite for their further engineering into a bioactive therapeutic. In our 
onging work we will focus on the development of bifunctional GPNMB-
aptamer/siRNA chimeras that combine the tumor-selective targeting 
properties of the aptamer domain with a cytotoxic activity associated with 
an siRNA moiety. Herein, an siRNA targeting cellular mRNAs crucial for 
cell survival will be fused to the GPNMB-aptamers and the anti-tumor 
effects of the chimeras assessed in vitro and in vivo.  
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Immune tolerance to tumors is often associated with accumulation of 
myeloid-derived suppressor cells (MDSC) and an increase in the number of 
T-regulatory cells (Treg). The inhibitory activity of MDSC is achieved by 
the production of arginase, reactive oxygen species, inducible nitric oxide 
synthase, and interleukin-10. In tumor-bearing mice, MDSCs can facilitate 
the generation of tumor-specific Tregs. We set out to determine the 
expression of microRNA and its target genes in MDSCs that are required 
for induction of Treg accumulation in tumor-bearing mouse. To begin to 
define how miRNAs could be involved in the regulation of gene expression 
on MDSC, microarray method was used to determine the miRNAs 
expressed highly on MDSC in tumor-bearing mouse. We demonstrated five 
miRNAs from MDSCs and Treg in melanoma-bearing mouse. The 
expression pattern of identified miRNAs was confirmed by real-time PCR. 
Potential target genes of microRNA were selected by Computational 
predictions using databases. The expression of potential target genes was 
checked by real-time PCR. The correlationships with microRNA and its 
target gene were determined. We postulate that identified miRNAs might 
play a role in certain basic functions on MDSC in melanoma-bearing 
mouse. 
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The pharmacokinetics and pharmacodynamics of systemically administered 
siRNA-based therapeutics can almost be completely decoupled. Once 
delivered to the desired site of therapeutic action, siRNA can affect gene 
knockdown for long time spans (c.a., one month for non-dividing cells), 
orders of magnitude longer than the plasma half-life of the siRNA or 
siRNA-delivery vehicle complex. Thus, determining dosing regimens for 
siRNA-based therapeutics is not straightforward due to the aforementioned 
phenomena. Our current work is focused on elucidating the kinetics of the 
siRNA-based therapeutics in animal cancer models. Using numerous types 
of in vivo studies, we are in the process of elucidating the kinetics of 
circulation, whole animal biodistribution, organ distribution, cellular 
distribution and gene inhibition in order to understand their relationships to 
anti-tumor outcomes. 
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Dominantly-inherited neurodegenerative diseases usually involve a 
deleterious gain-of-function by the mutant protein. By contrast, in myotonic 
dystrophy type 1 (DM1) there is a toxic gain-of-function by the mutant 
RNA (RNA dominance). The genetic basis for this effect is an expansion of 
CTG repeats in the 3′ untranslated region of DMPK, a gene encoding a 
protein kinase. Transcripts that contain an expanded CUG repeat (CUGexp) 
accumulate in nuclear foci and initiate a complex cascade of downstream 
events. For example, CUGexp binding proteins, such as, splicing factors in 
the Muscleblind-like (MBNL) family, become sequestered on the mutant 
RNA, causing misregulated alternative splicing of pre-mRNA. CUGexp 
transcripts also activate signaling pathways, compounding the problem with 
misregulated gene expression. This presentation will focus on the 
therapeutic use of antisense oligonucleotides (ASOs) in mouse models 
DM1. For example, splice blocker ASOs can be used to enforce the correct 
splicing of exons that are misregulated in the disease. However, this is a 
piecemeal approach that must be applied to each misregulated exon in turn. 
Blocker ASOs can also be used to bind to the CUGexp tract, thereby 
releasing proteins that are sequestered on the mutant RNA. This has several 
beneficial consequences, including a general correction of the alternative 
splicing defect. Finally, siRNAs can be used to target the toxic RNA for 
cleavage. Taken together, these observations suggest that oligonucleotide 
drugs offer a promising approach to develop an effective treatment for 
myotonic dystrophy. 
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Many neurological disorders are caused by expanded trinucleotide repeats, 
including Machado-Joseph Disease (MJD) and Huntington Disease (HD). 
MJD and HD are caused by expanded CAG repeats within the ataxin-3 
(ATXN3) and huntingtin (HTT) genes. Inhibiting expression of ATXN3 or 
HTT are promising therapeutic strategies, but indiscriminant inhibition of 
wild-type and mutant alleles may lead to toxicity. We hypothesized that 
expanded triplet repeat mRNA might be preferentially recognized by 
complementary oligomers. We observe selective inhibition of mutant 
ataxin-3 and HTT protein expression by peptide nucleic acid (PNA) and 
locked nucleic acid (LNA) oligomers targeting CAG repeats. Duplex RNAs 
were less selective, suggesting an advantage for single-stranded oligomers. 
Inhibiting mutant HTT expression protected cultured striatal neurons from 
an HD mouse model against glutamate-induced toxicity. Antisense 
oligomers that discriminate between wild-type and mutant genes on the 
basis of repeat length offer new options for treating MJD, HD, and other 
hereditary diseases. 
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Mammary serine proteinase inhibitor (maspin) is a multifaceted tumor 
suppressor gene controlling tumor cell proliferation, angiogenesis and 
metastatic spread for many types of cancer, including breast and lung 
cancer. Unlike other tumor suppressor genes, maspin is not mutated or 
deleted in tumor cells but its promoter is found epigenetically silenced in 
metastatic cells by aberrant promoter hypermethylation. In contrast, normal 
breast cells express high levels of maspin and the promoter is not found 
methylated. The epigenetic silencing of maspin in tumor cells offers a 
unique opportunity for therapeutic intervention by re-activation of the 
endogenous gene. Our lab has developed a novel approach to specifically 
re-activate maspin using engineered artificial transcription factors (ATFs). 
We have constructed several ATFs made of six-zinc finger (ZF) sequence-
specific DNA binding domains and linked to a transactivator domain. These 
ATFs target unique 18 base pair sites in the human proximal maspin 
promoter. We have shown that the ATFs are able to reactivate maspin 
expression in cell lines carrying a hypermethylated promoter. Furthermore, 
we have shown that ATFs synergize with chromatin remodeling agents 
presently in clinical trials to reactivate maspin expression, indicating that 
epigenetic silencing marks act as a partial blockade for the ATFs, probably 
by affecting the accessibility of the ATF-binding site. Furthermore, we have 
demonstrated that the ATFs are able to induce endogenous maspin 
expression in xenografts and metastasis models of breast cancer in nude 
mice. Concomitantly to maspin re-activation, we have shown that the ATFs 
induced tumor growth reduction ad metastasis suppression in vivo. In 
summary our work document the power of a novel therapeutic approach 
that uses ATFs to overcome the endogenous epigenetic silencing of tumor 
suppressors.  
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Triple helix-forming peptide nucleic acids (PNAs) can bind to polypurine 
regions in DNA in a sequence-specific manner. The resulting triplexes 
constitute an altered DNA structure that can stimulate DNA repair and 
recombination in a site-specific manner in human cells. Transfection of 
human cells with triplex-forming PNAs plus short single-stranded donor 
DNAs can produce targeted gene modification at frequencies of 2% or more 
in a single treatment. We have developed triplex-forming PNAs that bind 
with high affinity and specificity to a selected site in the CCR5 gene, which 
encodes a co-receptor for R5-tropic human immunodeficiency virus-1 
(HIV-1) that must be present at the cell surface for R5-viral entry. 
Individuals who possess a homozygous delta32 mutation in CCR5 express a 
truncated protein, reducing its expression at the cell surface and inhibiting 
HIV-1 from entering the cell. These individuals are almost completely 
resistant to R5-tropic HIV-1 infection and show no significant adverse 
phenotypes. One therapeutic strategy to mimic this naturally occurring 
inactivating mutation is PNA-mediated modification of CCR5. In a cell line 
model, we have shown the ability of a triplex-forming PNAs to induce 
recombination in the CCR5 gene at a frequency of 2.46% based on direct 
evaluation of 1870 single-cell derived clones. Gene targeting was verified 
by isolation of modified clones and analysis at the DNA, RNA, and protein 
levels. Importantly, PNA-mediated CCR5 modification was also shown to 
confer resistance to infection with HIV-1. This approach to target CCR5 
was also tested in primary human CD34+ hematopoietic stem cells (HSCs), 
and successful modification was demonstrated at both the DNA and RNA 
levels. CCR5 targeted human CD34+ HSCs were transplanted into NOD-
scid IL2Rγnull HLA A2.1 mice, and persistence of the gene modification 
was detected in donor-derived splenic CD4 lymphocytes more than four 
months post-transplantation. This work suggests a potential therapeutic 
strategy for permanently inactivating the CCR5 co-receptor in human HSCs 
from HIV-1 infected individuals, thereby creating a reservoir of virus-
resistant cells to preserve immune system function. 
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Myotonic dystrophy (DM) is the primary cause of adult onset muscular 
dystrophy that affects 1 in 8000 individuals worldwide. The main symptoms 
in DM include myotonia, insulin resistance, cardiac conduction defects, 
cataracts and altered central nervous system function. Myotonic dystrophy 
type 1 (DM1), which is the more common form in the United States, is 
caused by a CTG repeat expansion (to >4000 repeats) in the 3’ UTR of the 
dystrophia myotonica protein kinase (DMPK) gene. The expanded DMPK 
allele is transcribed to produce mRNAs containing long CUG repeats that 
accumulate in nuclear foci. The CUG repeat-containing RNA has a toxic 
gain-of-function that is the main cause of DM1 pathogenesis; therefore, 
eliminating the toxic RNA is anticipated to have a therapeutic effect.  
 
We chose to use antisense oligonucleotides (ASOs) as our approach to 
target degradation of the repeat RNA. ASOs containing CAG repeats are 
expected to hybridize to the expanded CUG repeats, forming a DNA-RNA 
hybrid that is a substrate for RNase H-mediated degradation of the mutant 
RNA. ASOs can be modified to form chimeric oligonucleotides termed 
“gapmers”, which contain phosphorothioate-modified DNA in the center 
flanked with three or four locked nucleic acids (LNA) on both ends. This 
provides both nuclease resistance and highly efficient mRNA cleavage. We 
tested three different ASO gapmers in cells transiently expressing 960 CUG 
repeats, and all of them resulted in a >90% knock-down of the repeat RNA. 
We are currently using electroporation to deliver gapmer ASOs into skeletal 
muscle tissue of a DM1 mouse model developed in our lab [PNAS 105, 
2646 (2008)] to determine their efficacy in vivo. Recently, RNase-H-
inactive CUG-repeat-binding morpholinos have been shown to promote the 
release of proteins bound to the long repeats and dissociate RNA foci 
[Science 325, 336 (2009)]. We are testing the possibility that combined 
administration of morpholinos with the gapmers will enhance the knock-
down efficiency.  
There is currently no known cure for DM1, hence the goal of our studies is 
to test a potential therapeutic approach for this disease which may provide 
insight for other RNA-dominant disorders. 
 
   This project is supported by the Muscular Dystrophy Association.  
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Huntington’s disease (HD) is a devastating disease for which currently no 
therapy is available. It is a progressive autosomal dominant 
neurodegenerative disorder that is caused by a CAG repeat expansion in the 
HD gene, which results in an expansion of polyglutamines at the N-terminal 
end of the huntingtin (htt) protein, and the accumulation of cytoplasmic and 
nuclear aggregates in neurons. The polyglutamine expansion results in a 
toxic gain of function for the huntingtin protein and plays a central role in 
the disease. The size of this expansion has a direct link to the aggregation-
proneness as well as the severity of pathological and clinical features.  
Here, we make use of fully modified 2’OMePS antisense oligonucleotides 
(AONs) as a therapeutic strategy to effectively reduce both htt transcript 
(agarose gel and quantitative PCR) and protein levels (Western Blot and 
time resolved FRET) in patient derived HD fibroblasts. The (CUG)7 AON 
is a promising therapeutic tool to reduce mutant htt in HD. Evidence in a 
Spinocerebellar Ataxia 3 (SCA3) fibroblast cell line suggests that (CUG)7 
AON could also be effective in other polyglutamine neurodegenerative 
diseases with a prolonged pure CAG repeat. 
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Spinal Muscular Atrophy (SMA) is a genetic disease characterized by 
progressive degeneration of motor neurons in the anterior horn of the spinal 
cord, which in turn leads to severe muscle weakness and atrophy. SMA is 
caused by deletion or loss-of-function mutations in the Survival-of-motor-
neuron (SMN1) gene. The paralogous SMN2 gene, present in one or more 
copies in all SMA patients, attenuates the severity of SMA, but expresses 
only a low level of full-length SMN protein, due to alternative splicing that 
results in inefficient inclusion of exon 7. Increasing the extent of SMN2 
exon 7 inclusion to express more full-length, functional SMN protein in 
motor neurons is a promising approach to treat SMA. Previously, we 
identified an optimal 2’-O-(2-methoxyethyl) (MOE) 18mer antisense 
oligonucleotide (ASO) that targets an hnRNP A1 bipartite motif in an 
intron-7 splicing silencer (ISS-N1) and efficiently promotes SMN2 exon 7 
inclusion in liver and kidneys of transgenic mice after systemic 
administration. Because ASOs do not cross the blood-brain barrier, we 
explored direct delivery to the mouse central nervous system. Using a 
surgically implanted micro-osmotic pump, the ASO (dubbed ISIS-SMNRx) 
was delivered into cerebrospinal fluid through the right lateral ventricle in 
adult Smn-/- type-III SMA mice carrying a human SMN2 transgene. Dose-
response studies revealed that intracerebroventricular (ICV) infusion of the 
18mer ASO increased SMN2 exon 7 inclusion in spinal cord to ~90%, 
compared to ~10% in saline-treated mice. Western blotting and 
immunohistochemical analysis demonstrated a robust increase of the human 
transgenic SMN protein levels in spinal-cord motor neurons. We are using 
this and other ICV delivery methods, in combination with available SMA 
mouse models, to optimize the effectiveness of the ASO, characterize 
phenotypic improvement, and establish a time window for effective 
treatment. Our data show that ISIS-SMNRx is a promising drug candidate 
for SMA therapy. 
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Objective: AVI BioPharma in collaboration with the MDEX consortium 
have identified a PMO to skip dystrophin exon 51 in DMD patients, restore 
the reading frame and enable dystrophin expression. Here, we test 6 PMO 
doses to select an effective, well tolerated dose for subsequent registration.  
Method: Open label, dose escalation study in ambulant DMD boys aged 5-
15 years with relevant deletions, of 12 weekly administrations of AVI-4658; 
14 week follow up with muscle biopsy to assess dystrophin expression. 
Clinical efficacy (6 minute walk), skeletal muscle, pulmonary and cardiac 
function is being assessed. Safety assessment includes adverse events, 
physical examinations and laboratory tests – including hematology, 
coagulation studies, chemistry and anti-dystrophin antibodies. A DSMB 
guided dose escalation decisions (across 6 doses: 0.5, 1.0, 2.0, 4.0, 10.0 and 
20.0 mg/kg).  
Results: Study fully enrolled 19 patients by Dec 2009. All doses well 
tolerated (ongoing at 20mg/kg). No Drug Related SAEs or severe AEs 
reported so far. To date, maximum single dose is 900mg and cumulative 
PMO dose 10800mg. Biopsies from first 4 cohorts showed exon skipping at 
2 and 4 mg/kg and 1 patient with 20% increase in number of dystrophin 
positive fibres.  
Conclusion: Study drug well tolerated to date. Dosing and follow up 
continue on schedule. These preliminary data bode well for safe long term 
administration in Duchenne patients, and suggests clinically meaningful 
dystrophin expression can be expected following systemic administration. 
Preliminary, laboratory data from the remaining cohorts is due in 2Q and 
full clinical results in 3Q 2010.  
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Background: Single-stranded RNA viruses represent the leading edge of 
emerging infectious disease. The challenges to drug discovery and 
development are numerous and include: a) efficient in replication to 
produce high viral titers, b) present unstable genome sequences as 
quaisispecies, and c) the infections interfere with effective immune 
responses. Methods: Studies were initiated to survey targeting genomes of 
single-stranded RNA viruses from a variety of viral families to determine 
effective strategies. The most extensive investigations have led to 
therapeutics in development for Zaire Ebolavirus (AVI-6002) and Lake 
Victoria Marburgvirus (AVI-6003). The strategies have utilized a novel 
phosphorodiamidate morpholiono oligomer with two to six positively 
charged linkages referred to as PMOplus. Results: Screening the viral 
genome of Zaire Ebolavirus led to effective targeting of VP35 and VP24 
which are combined in AVI-6002. Similar screening in Lake Victoria 
Marburgvirus led to VP24 and NP targets which are combined in AVI-
6003. The PMOplus agents have been effective in mouse, guinea pig and 
nonhuman primate lethal challenge studies. Both AVI-6002 and AVI-6003 
demonstrate dose dependent antiviral activity, preservation of the immune 
response and provide significant survival benefit. Further, the position of 
the positive linkages in PMOplus agents offers an effective counter to viral 
resistance. More recent studies have explored the RNA-therapeutic 
approach to manipulation of the immune response to provide a more 
comprehensive approach to development of therapeutics for emerging 
infectious disease. Conclusion: Together, the strategies for targeting viral 
the genome as an antiviral and the host immune response to infection can be 
employed for effective and rapid therapeutic development that is necessary 
to combat emerging infective diseases. 
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Antisense-mediated reading frame restoration is presently the most promising 
therapeutic approach for Duchenne muscular dystrophy (DMD). In this 
approach, antisense oligoribonucleotides (AONs) induce specific exon skipping 
during pre-mRNA splicing to restore the disrupted open reading frame and 
allow synthesis of internally deleted, partly functional Becker-like dystrophin 
proteins. The approach is theoretically applicable to over 70% of all patients. 
Proof of concept has been achieved in cultured muscle cells from patients 
carrying different mutation types, in the mdx mouse and dog models and 
recently in patients as well. In a first trial in 2006, we showed exon 51 skipping 
and dystrophin restoration in each patient after local intramuscular AON 
injections. A subsequent trial where patients are treated systemically has 
recently been completed successfully and a 6-months followup trial using the 
most effective dosage is underway by Prosensa (van Deutekom et al. This 
meeting). 
Due to AON turnover, repeated treatment is necessary. Therefore, long term 
safety and efficacy of 2’O-methyl phosphorothioate AON treatment was tested 
in mouse models with varying levels of severity: mdx mice (mild phenotype) 
and mdx mice with one utrophin allele (mdx +/-; intermediate phenotype). 
Comparison of different routes of administration revealed that the AON load in 
muscle was similar for intravenous (IV), intraperitoneal (IP) and subcutaneous 
(SC) delivery, while the load in liver and kidney was much reduced for IP and 
SC injections. Thus, mice were treated with weekly SC injections of 200 mg/kg 
for up to 6 months. This was well tolerated during treatment and liver and 
kidney weights and serum parameters were similar for 4, 8, 12 and 24 week 
treated mice compared to saline treated controls at the end of treatment. In the 
mdx and mdx +/- mice treatment resulted in significantly improved serum 
creatine kinase (marker for muscle quality) and rotarod running time (marker 
for muscle function) compared to the controls. In the more severely affected 
mdx +/- mice the therapeutic effect was larger. Time course experiments 
revealed that exon skipping levels increased for the first 12 weeks, but remained 
constant after that. Protein analysis revealed a similar pattern.  
These results indicated that long term treatment with 2’-O-methyl 
phosphorothioate AONs is safe and efficient in dystrophic mouse models, 
which is encouraging for future long term trials in patients.  
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Duchenne muscular dystrophy (DMD) affects 1 in every 3500 males 
worldwide and results from a mutation of the dystrophin gene. AVI 
BioPharma is currently in clinical development with AVI 4658, a 
Phosphorodiamidate Morpholino Oligomer (PMO) drug, designed to induce 
exon 51 skipping and restore dystrophin expression in a subset of DMD 
patients. The objective of these preclinical studies was to evaluate the 
potential toxicity of AVI-4658 upon repeated administration. Cynomolgus 
monkeys were dosed once weekly for 12 weeks with AVI-4658 at levels up 
to and including the maximum feasible dose of 320 mg/kg/injections, either 
intravenously or subcutaneously. AVI-4658 was well tolerated at dose 
including 320 mg/kg/injection, with no adverse effects. Findings were 
generally limited to the kidney, and included basophilic granules, basophilic 
tubules and instances of vacuolation at the highest dose levels. No evidence 
of kidney function change was detected, as evidenced by clinical chemistry 
and urinalysis evaluations. Kidney findings were generally reversible, as 
evidenced in the 28 day recovery groups. This study demonstrates the 
remarkable safety of AVI-4658 in non-human primates. In the murine 
study, wild type and dystrophic mdx mice were dosed once weekly for 12 
weeks with AVI-4658 up to 960 mg/kg/injections (maximum feasible in 
mice), either intravenously or subcutaneously. AVI-4658 was well tolerated 
at all doses including 960 mg/kg/injection, with no adverse effects. Findings 
were generally limited to the kidney, and included basophilic granules, 
basophilic tubules and instances of vacuolation at the highest dose levels. 
No evidence of kidney function change was detected, as evidenced by 
clinical chemistry and urinalysis evaluations. Kidney findings were 
generally reversible, as evidenced in the 28 day recovery groups. This study 
demonstrates the remarkable safety of AVI-4658 in both healthy and 
dystrophic rodents. Similar findings were seen in a separate study in which 
AVI-4225, designed to restore dystrophin expression in mdx mice, was 
administered in the identical manner and doses. In addition, mechanism of 
action driven improvement in muscle pathology was detected in a dose 
dependent manner in the AVI-4225 study. The above data demonstrate the 
extraordinary preclinical safety profile of PMOs compounds, and in 
particular AVI-4658, for use as exon skipping drugs for the treatment of 
DMD. 
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Carcinoembryonic antigen related cell adhesion molecule-1 (CEACAM1) is 
a cell surface glycoprotein mainly expressed on the luminal surface of 
epithelial cells. In humans, CEACAM1 pre-mRNA undergoes alternative 
splicing to produce 11 splice variants. The two major splice variants of 
CEACAM1 are generated by the inclusion (CEACAM1-L) or exclusion 
(CEACAM1-S) of exon 7. The link between CEACAM1 downregulation 
and breast cancer has been known for more than a decade. However, 
CEACAM1 was overlooked as a target for therapeutic intervention 
apparently because its activity is downregulated in only 30% of breast 
cancers. We looked at the existing paradigm from a different perspective. 
We hypothesized that a physiological S:L ratio is required for normal breast 
morphology and altered ratio may disrupt tissue architecture thereby 
initiating tumorigenesis. To test our hypothesis, we asked the following 
questions: (1) Will an alteration in the ratio of CEACAM1 splice variants 
induce phenotypic changes in acinar morphogenesis of the non-malignant 
human mammary epithelial cell line (MCF10A)? (2) Will changing the 
relative balance of CEACAM1 splice isoforms in ZR75, a tumor mammary 
epithelial cell line that does not form lumena when grown in Matrigel, 
revert to normal morphology or lose transformed phenotype? We found that 
antisense oligonucleotide mediated shift in S:L ratio disrupted acinar 
morphology in MCF10A cells, a salient feature of early glandular epithelial 
cancer. Importantly, altered S:L ratio significantly reduced invasive 
potential of malignant breast cancer cell line ZR75. Insights from this study 
will not only be important to understand the role of isoform ratios in 70% of 
breast cancers that continue to express CEACAM1 but may also identify 
new target for breast cancer intervention. 
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siRNA induced RNAi responses have great potential to treat human disease, 
especially cancer and viral infections. However, siRNAs are negatively 
charged, 14,000 Dalton macromolecules with no bioavailability to enter 
cells and siRNA cellular delivery remains a significant rate-limiting step for 
development of RNAi therapeutics. To address the siRNA delivery 
problem, we developed a Peptide Transduction Domain-dsRNA Binding 
Domain (PTD-DRBD) fusion protein. DRBDs bind siRNAs in a sequence-
independent manner that masks the negative charge, allowing for PTD-
mediated siRNA delivery. PTD-DRBD mediated delivered of EGFR and 
Akt2 siRNAs induced a synthetic lethal RNAi response that significantly 
increased longevity in intracerebral glioblastoma mouse models in vivo. 
PTD-DRBD fusion proteins begin to address the siRNA delivery problem 
with a high efficiency and low toxicity, biodegradable platform. 
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Systemic delivery of small interfering RNA (siRNA) to target tissues 
remains a major hurdle for the widespread therapeutic application of RNAi. 
We have recently demonstrated delivery of cytotoxic siRNAs to prostate 
cancer cells following systemic administration (Dassie, 2009). The siRNAs 
were conjugated to a synthetic RNA ligand (aptamer) with affinity for 
prostate specific membrane antigen (PSMA), an antigen expressed on 
prostate cancer cells.  
 
While encouraging, the extended use of RNA aptamers as a delivery tool 
for siRNAs awaits the identification of RNA aptamer sequences capable of 
targeting and entering the cytoplasm of many different cell types. To enable 
the isolation of cell-type specific cell-internalizing RNA aptamers, we have 
developed a modified cell-based SELEX (systematic evolution of ligands 
by exponential enrichment) methodology which we refer to as cell-
internalization SELEX. This approach allows for the rapid isolation of RNA 
aptamer sequences that are efficiently internalized into the target cells. We 
demonstrate the usefulness of this approach for isolating cell-internalizing 
RNA aptamers that target specific cell types (e.g. cancer cells vs. normal 
cells) or specific surface antigens expressed on cells. Conjugation of these 
cell-internalizing aptamers to siRNAs results in efficient delivery of the 
siRNA cargo into the cytoplasm of the target cells enabling robust gene-
specific silencing. The development and future refinement of this 
technology may facilitate the widespread use of RNAi for clinical 
applications.  
 
Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, 
Meyerholz DK, McCaffrey AP, McNamara JO 2nd, Giangrande PH. Systemic 
administration of optimized aptamer-siRNA chimeras promotes regression of 
PSMA-expressing tumors. Nat Biotechnol. 27(9):839-49 (2009). PMCID: 
PMC2791695.  
 45 
ADVANCES IN THE THERAPEUTIC USE OF RNA INTERFERENCE 
(RNAi) 
 
P. Pavco, K. Bulock, L. Libertine, J. Cardia, K. Flannery-Rossi, J. 
Metterville, T. Drew, M. Byrne, J. Kamens, G. Ford, A. Rodgers, A. 
Khvorova 
RXi Pharmaceuticals, Corp., 60 Prescott Street, Worcester, MA, 01605 
 
Just over a decade has passed since the discovery of the RNAi mechanism (Fire et 
al., 1998, Nature 391:806-11). In this relatively short time, numerous siRNA-based 
candidates have moved from discovery research to clinical testing in humans. This 
presentation will include an overview of this progression and discuss steps being 
taken to advance improved RNAi compounds into therapeutic development.  
 
Early human trials focused on clinical indications for which direct administration of 
siRNA to the site of disease was possible. These included the eye (2004, direct 
intraocular injection) and lung (2006, inhalation). Trials using ‘direct delivery’ to 
the kidney via intravenous administration (2007) and transdermal injection for skin 
(2008) followed. Early siRNAs often included chemically modified nucleotides (2’-
O-methyl, 2’-fluoro) and phosphorothioate linkages to improve stability while 
maintaining potency. Continued research on chemistry configuration as well as 
selection and design parameters has led to RNAi compounds with enhanced 
therapeutic oligonucleotide properties and resolution of some potential issues of 
non-specificity and immune stimulation.  
 
A major hurdle in the development of RNAi as a broad therapeutic class is delivery 
of the RNAi compound to the appropriate tissue and efficient intracellular uptake. 
Many delivery modalities are being explored, most of which involve formulating the 
RNAi compound with additional components, often lipids, to form complex delivery 
vehicles intended to improve the compound’s PK parameters and allow increased 
distribution to the appropriate tissues. Formulations used in human trials to date 
include a targeted cyclodextrin-based ‘polymer’ to deliver the siRNA payload to 
specific tumor cells (2008) and a lipid nanoparticle for improved delivery to the 
liver (2009).  
 
Our alternative delivery approach is to alter the structural and chemical composition 
of siRNA to create novel RNAi compounds with efficient cellular uptake. These 
‘self-delivering’ RNAi compounds (sd-rxRNA™) retain potent activity, stability, 
and reduced immune stimulation and are rapidly and effectively taken up by cells 
without a transfection reagent or delivery vehicle. Specific proprietary chemical 
modifications and patterns and reduced oligonucleotide content are required. 
Analyses of fluorescently-labeled sd-rxRNAs demonstrate efficient cellular 
internalization in a variety of cultured and primary cells in vitro and following direct 
administration in vivo. Significant reduction of targeted mRNA in vivo following 
local administration supports the use of sd-rxRNAs for clinical applications where 
direct administration is possible.  
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Mouse models with liver-specific expression of firefly luciferase have been 
developed that enable a real-time, longitudinal and non-invasive assessment 
of siRNA-mediated gene silencing in hepatocytes of live animals via 
bioluminescence imaging. Using these models, a set of lipid nanoparticles 
(LNP), composed of cationic lipids, a PEG lipid and cholesterol, were 
tested for their abilities in delivering a luciferase siRNA to the liver via 
systemic administration. A dose-dependent luciferase knockdown by 
LNP/siRNA assemblies was measured by in vivo bioluminescence imaging, 
which well correlated with the results from parallel ex vivo analyses of 
luciferase mRNA and protein levels in the liver. RNAi-mediated target 
silencing was further confirmed by detection of the target mRNA cleavage 
site. A single dose of LNP02L at 3 mg/kg (siRNA) caused >90% reduction 
of luciferase expression and the target repression lasted for at least 10 days. 
With identical components, LNPs containing 2% PEG are more potent than 
those with 5.4% PEG. Our results demonstrate that these mouse models 
with tissue-specific expression of luciferase provide a powerful tool for a 
high throughput evaluation of siRNA delivery vehicles and that the molar 
ratio of PEG lipid can affect the efficacy of LNPs in silencing liver targets 
via systemic administration. 
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Alternative splicing has emerged as an important target for molecular 
therapies. Splice-switching oligonucleotides (SSOs) modulate alternative 
splicing by hybridizing to pre-mRNA sequences involved in splicing and 
blocking access by splicing factors. Recently, the efficacy of SSOs has been 
established in various animal disease models; however, the application of 
SSOs against cancer targets has been hindered by poor in vivo delivery of 
antisense therapeutics to tumor cells. We previously showed that redirection 
of Bcl-x pre-mRNA splicing from anti-apoptotic Bcl-xL to pro-apoptotic 
Bcl-xS induced apoptosis and enhanced chemosensitivity in breast and 
prostate cancer cells. In this study, the effect of SSO-induced Bcl-x splice-
switching on metastatic melanoma was assessed in cell culture and B16F10 
tumor xenografts. SSOs were delivered in vivo using a liposome-
polycation-DNA nanoparticle. Administration of nanoparticle with Bcl-x 
SSO resulted in modification of Bcl-x pre-mRNA splicing in lung 
metastases and reduced tumor burden, while nanoparticle alone or 
formulated with a control SSO had no effect. Our findings demonstrate in 
vivo anti-tumor activity of SSOs that modulate Bcl-x pre-mRNA splicing. 
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Breast cancer, one of the leading causes of cancer death worldwide, must be 
treated by drugs with multiple activities due to its complex nature. 
Disregulated in many types of cancer, miRNAs are being studied intensely 
as targets for breast cancer therapeutics.  
For example, elevated miR-21 reduced the protein expression levels of 
tumor suppressor proteins including PDCD4, TPM1 and PTEN in breast 
carcinoma, contributing to increased breast cancer cell proliferation, 
microfilament destabilization, survival, invasiveness, and metastatic 
transformation. In contrast, attenuation of let-7 enabled increased KRAS 
and NRAS proto-oncogene expression, both in vitro and in vivo. The 
differential expression of some let-7 isoforms correlates with progesterone 
receptor status, lymph node metastasis, or high proliferation index in breast 
cancer. Similarly, attenuation of miR-17-5p elevated expression of AIB1 
protein, which acts as a rate-limiting factor for estrogen-mediated and 
E2F1-mediated growth in breast cancer cells.  
We hypothesize that complementary oligomers that can inhibit or mimic the 
above miRNAs will re-establish the balance of homeostasis. Breast cancer 
cell-restricted miRNA regulation will be tested by introducing sequence-
specific peptide nucleic acid (PNA) 12-mers conjugated to a C-terminal 
epidermal growth factor (EGF) analog to enable EGFR-mediated 
endocytosis into those cells that overexpress EGF receptor (EGFR, Her-1, 
erb-B1). We have validated breast cancer cell uptake and cytoplasmic 
localization of a fluorescently labeled peptide previously reported to bind to 
EGFR.  
Uptake and intracellular trafficking of fluorophore-PNA-EGF analogs vs. 
PNA and peptide mismatch controls are underway. The miRNA target 
protein expression levels in breast cancer cells following treatments will be 
compared to those in cells treated with controls. Changes in breast cancer 
cell migration, microfilament organization, proliferation and survival will 
be analyzed in cells treated with PNA-EGF analogs, vs. mismatch controls. 
Supported by DOD W81XWH-09-1-0577. 
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MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH 
SYNTHETIC OLIGONUCLEOTIDES 
 
Sudhir Agrawal  
 
Idera Pharmaceuticals, Inc., Discovery, 167 Sidney Street, Cambridge, MA, 
02139 
 
Synthetic oligonucleotides comprising various nucleotide sequences, 
lengths, and chemical modifications are currently being studied as 
therapeutic agents based on various mechanisms of action. Oligonucleotides 
are transported into intracellular compartments by endocytosis. Toll-like 
receptors (TLR) 3, 7, 8, and 9 are expressed in endosomes, and are 
receptors that recognize foreign RNA and DNA. TLR3 recognizes double-
stranded RNA, TLR7 and TLR8 recognize single-stranded RNA and TLR9 
recognizes DNA containing unmethylated CG dinucleotides . Under certain 
pathological conditions TLR7 and TLR9 are also known to recognize self 
RNA and DNA present within immune complexes. Through extensive 
structure-activity relationship studies, we have observed that TLR7-, 8-, and 
9-mediated immune responses can be modulated depending on the synthetic 
DNA and RNA sequences, nucleotide motifs, secondary structures, 
accessibility of the 5’- and 3’-ends, and chemical modifications. Activation 
of immune responses through these receptors has broad therapeutic 
potential for the treatment of a range of diseases, including cancer, 
infectious diseases, asthma and allergies, and use as adjuvants with 
vaccines. In addition, blocking immune responses mediated through TLR7 
and TLR9 has applications for potential treatment of autoimmune diseases, 
including lupus, arthritis, and psoriasis. Several compounds designed 
through these programs are at various stages of clinical trials for a broad 
range of diseases. 
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UNDERSTANDING THE IMMUNE EFFECTS OF THERAPEUTIC 
NUCLEIC ACIDS  
 
Arthur M Krieg  
 
Pfizer, OTU, 620 Memorial Drive, Cambridge, MA, 02139 
 
Immune stimulatory effects have complicated the therapeutic development 
of antisense oligodeoxynucleotides (ODNs) and small interfering RNAs 
(siRNAs). Both antisense and siRNA molecules can induce innate 
immunity through Toll-like receptors (TLRs) and/or the cytoplasmic 
retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs). A subset of 
TLRs, including TLR3, TLR7, TLR8, and TLR9, are expressed 
intracellularly within one or more endolysosomal compartments, and detect 
single-stranded CpG DNA (TLR9) and certain single-stranded RNA motifs 
(TLR7 and 8), or double-stranded RNA (TLR3). Signaling via these 
receptors can activate several types of immune and non-immune cells, with 
resultant innate immune stimulation and the production of type I interferon 
and pro-inflammatory cytokines and chemokines. Unless appropriate 
controls are performed, the TLR- and RLR-driven immune stimulatory 
effects of molecules designed as antisense ODN or RNAi can be mistakenly 
attributed to the intended mechanism of action. 
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IMPROVING THE THERAPEUTIC PIPELINE 
 
Andrew D Ellington  
 
University of Texas at Austin, Department of Chemistry and Biochemistry, 
Institute for Cell and Molecular Biology, 1 University station A4800, 
Austin, TX, 78712 
 
While it is uncertain whether and what academics have to contribute to drug 
development pipelines, the fact remains that nucleic acid therapeutics show 
great promise. However, nucleic acids as a therapeutic class must now be 
subjected to a long and arduous accumulation of knowledge that may lead 
to their adoption as drugs. In this, they are at a severe disadvantage relative 
to protein drugs, such as antibodies, which started their commercial lives 
much closer to therapeutic relevancy and are already in use for a variety of 
indications. I briefly consider the relatively minor role that discovery plays 
in the pipeline, and then move on to academic endeavors that address (a) 
possibilities for the large-scale production of complex nucleic acid 
therapeutics, (b) the still largely unexplored realms of nucleic acid 
pharmacokinetics and bioavailability, and (c) the unique side-effects that 
will likely be associated with nucleic acid pharmaceuticals and that will 
have to be dealt with into the future. 
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PRO- TO ANTI-ANGIOGENIC SWITCH:  CHANGING VEGFR 
ACTIVITY BY SPLICING/POLYADENYLATION INTERFERENCE 
 
Sandra Vorlova, Luca Cartegni  
 
Memorial Sloan-Kettering Cancer Center, Memorial Pharmacology and 
Chemistry, 1275 York Avenue, New York, NY, 10021 
 
The targeting of angiogenic signal transduction pathways represents a 
promising emerging strategy in solid tumor therapy. Vascular endothelial 
growth factor (VEGF) is a potent vascular endothelial cell mitogen and a 
crucial mediator of tumor angiogenesis.  
 
VEGF expression is elevated in tumors and it acts on endothelial cells, 
which express two high-affinity receptors, VEGFR-1 (Flt-1) and VEGFR-2 
(Flk-1/KDR). A soluble truncated isoform of VEGFR-1 (sFlt-1) contains 
only the first six, extra-cellular Ig-like domains but lacks the 
transmembrane and TK domains due to alternative 
splicing/polyadenylation. This endogenously encoded soluble receptor 
functions as a specific, high-affinity antagonist of VEGF signaling.  
 
We developed a new strategy for an antisense-based therapy by re-directing 
VEGFR-1 and VEGFR-2 alternative splicing/polyadenylation to the soluble 
VEGFR-1 isoform (sFlt-1) and a newly identified soluble VEGFR-2 
(sKDR). Treatment exerts negative regulatory effects by three main 
mechanisms: elimination of the active VEGFR isoform, sequestering VEGF 
(similar to the action of VEGF Trap) and inducing dominant-negative 
receptor heterodimers with remaining full length VEGFRs.  
 
We identified target mRNA sequences in VEGFR-1 and VEGFR-2 to 
modulate sFlt-1 and sKDR expression and developed specific antisense 
compounds (morpholinos), covalently coupled to cell-delivering moieties, 
to modulate endogenous VEGFR splicing/polyadenylation and.  
 
This novel anti-angiogenic strategy based on alternative 
splicing/polyadenylation offers the advantage of simultaneously knocking 
down the pathological target while introducing a natural dominant-negative 
isoform. 
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GENE SILENCING BY SYNTHETIC U1 ADAPTORS 
 
Rafal Goraczniak1, Mark A Behlke2, Chris Miller3, Michael Neubauer3, 
Wen-Pin Yang3, Samuel I Gunderson1  
 
1Rutgers University, Molecular Biol. & Biochem, 604 Allison Road, 
Piscataway, NJ, 08854, 2Integrated DNA Technologies, Mol. 
Genetics/Biophysics, 1710 Commercial Park, Coralville, IA, 52241, 
3Bristol-Myers Squibb, Dept of Applied Genomics, P.O. Box 5400, 
Princeton, NJ, 08543 
 
Historically, there have been two major types of gene silencing platforms, 
RNAi and traditional antisense. Here we present new data on a recently-
published alternative gene silencing method called U1 Adaptor that is based 
on a novel mechanism. The U1 Adaptor is a single stranded oligonucleotide 
having an annealing domain that targets gene-specific pre-mRNA in the 
terminal exon by conventional basepairing and a U1 domain that basepairs 
to the U1 snRNA component of the U1 snRNP splicing factor. This 
tethering of U1 snRNP to pre-mRNA inhibits 3' end processing (ie. polyA 
tail addition), hence leading to reduced mRNA levels. U1 Adaptors 
specifically inhibit both reporter and endogenous genes with IC50 values of 
<1nM routinely being achieved. Targeting a single gene with multiple U1 
Adaptors or an Adaptor and siRNA leads to enhanced "deep" silencing, the 
latter consistent with their having distinct mechanisms that act in distinct 
cellular compartments. Such deep silencing will be especially useful for 
those genes where modest levels of silencing do not achieve the desired 
outcome. New microarray studies, comparing U1 Adaptors with siRNAs, 
show U1 Adaptors are to a large degree as specific as siRNAs and have 
identified U1 Adaptor-response specific genes, ie. those genes whose 
changes in expression levels depends on the basic U1 Adaptor design. U1 
Adaptors have distinct advantages over other methods including: 1) the 
ability to maintain activity even when all bases of the molecule are 
modified and when covalently bound to cell-specific targeting groups (such 
as peptides), 2) lack of immune stimulation, and 3) lack of off-target effects 
on particular cellular processes. Through use of delivery agents, we will 
present data on silencing of target genes in mice. 
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THE P53 TARGET WIG-1 REGULATES MRNA STABILITY AND IS 
NECESSARY FOR NORMAL EMBRYONIC DEVELOPMENT 
 
Anna Vilborg 1, Björn Rozell2, Cinzia Bersani1, Klas G Wiman1, Margareta 
T Wilelm3  
 
1Karolinska Institutet, Oncology-Pathology, Karolinska University Hospital, 
Solna, Stockholm, 17176, Sweden, 2Karolinska Institutet, Laboratory 
Medicine, Karolinska University Hospital, Huddinge, Huddinge, 14186, 
Sweden, 3Karolinska Institutet, Microbiology, Tumor and Cell Biology, 
Karolinksa Institute, Stockholm, 17177, Sweden 
 
The p53 tumor suppressor triggers cell cycle arrest, apoptosis, or a variety 
of other responses after exposure to cellular stress. p53 exerts its biological 
function at least in part through transcriptional transactivation of target 
genes. One such gene is wig-1 (for wild-type p53 induced gene 1). Our 
biochemical studies have revealed that the Wig-1 protein binds double 
stranded (ds) RNA with high affinity in vitro and in living cells. We have 
also shown that Wig-1 binds to a U-rich region in p53 mRNA and stabilizes 
it by preventing deadenylation, the first and rate limiting step of mRNA 
degradation. We show here that Wig-1 is an essential protein, since 
knockout mice die during embryonic development and the ratio of 
heterozygous to wildtype mice is less than expected. Many factors involved 
in processes such as embryonic development and cancer are regulated at the 
level of mRNA stability, through AU-rich elements as well as through other 
mechanisms. Our preliminary data indicate that Wig-1 regulates other 
mRNA containing U-rich or AU-rich sequences apart from p53, some of 
which, alongside with p53, are potentially interesting targets for cancer 
therapy. Once verified, we aim to use RNA therapeutics to modify their 
regulation by Wig-1. 
 55 
THE REGULATION OF TRANSCRIPTION-DRIVEN R-LOOP 
FORMATION AND ITS THERAPEUTIC IMPLICATIONS 
 
Tsai-Kun Li1,2, Shu-Yu Huang1, Chen-Yu Wen1, Yu-Chen Yang1  
 
1College of Medicine, National Taiwan University, Department and 
Graduate Institute of Microbiology, No. 1, Sec. 1, Jen-Ai Rd., Taipei, 
10018, Taiwan, 2National Taiwan University, Center for Biotechnology, 
No. 81, Chang-Hsin St., Taipei, 10672, Taiwan 
 
The RNA editing and DNA deamination model have been proposed as the 
action mechanisms of activation-induced deaminase (AID)-mediated 
immunoglobulin (Ig) recombination for antibody diversification. Here, we 
present experimental results supporting that the R-loop, a RNA-DNA 
hybrid with a single-stranded DNA region, as the targeting substrate for 
AID. A bacterial genetic model was further employed to explore the 
regulations and recombination pathways involved in this AID-mediated 
post-transcriptional control of gene expression. To our surprise, we have 
observed that AID expression also led to bacterial killing and the DNA 
damage-associated cellular filamentation. Thus, unregulated deamination 
and subsequent DNA breaks by AID are mutagenic and lethal to cells. This 
is in agreement with the potential adverse effect of AID that its activity on 
non-Ig genes is responsible for the generation of chromosome translocations 
and to lymphomagenesis. In addition, transcripts of Ig switch regions have 
been shown to preferentially form R-loop both In Vitro and in cells. 
Currently, the potential of nuclear RNAs, particularly for those containing 
sequences from Ig switching regions, as anti-cancer agents in the absence 
and presence of AID is under investigation. Preliminary results have 
showed that transfection of RNA oligos caused chromosomal DNA 
breakage and cell killing. With advanced knowledge on the newly identified 
roles of small RNAs, it is therefore important to understand the underlying 
mechanism(s) for the anti-tumor activity of RNA oligos and the potential 
contribution of R-loop/AID in this RNA-mediated cell killing.  
Participant List
Dr. Annemieke Aartsma-Rus
Leiden University Medical Center
a.m.rus@lumc.nl
Dr. Sudhir Agrawal
IDERA Phamaceuticals
sagrawal@iderapharma.com
Dr. Sidney Altman
Yale University
sidney.altman@yale.edu
Dr. Sandro Alves
Institut du Cerveau et de la Moelle Epinière
sandropfalves@gmail.com
Ms. Lisbeth Andersen
Aarhus University
lma@mb.au.dk
Mr. John Bauman
University of North Carolina
johnabauman@gmail.com
Dr. Rick Becker
Duke University
becke021@mc.duke.edu
Dr. Pilar Blancafort
University of North Carolina 
pilar_blancafort@med.unc.edu
Dr. Raymond Brown
Research Consultant
ray-brown@att.net
Dr. Virginia Burns
Duke University
virginia.burns@duke.edu
Dr. Luca Cartegni
Memorial Sloan-Kettering
cartegnl@mskcc.org
Dr. Changpo Chen
Thomas Jefferson University
changpo.chen@jefferson.edu
Prof. Han-Yi Chou
National Taiwan University
hyechou@ntu.edu.tw
Ms. Lisa Cillessen
Missouri State University
cillessen3@live.missouristate.edu
Dr. David Corey
UT Southwestern Medical Institute
david.corey@utsouthwestern.edu
Dr. Peter de Visser
Prosensa Therapeutics BV
p.devisser@prosensa.nl
Dr. Steven Dowdy
HHMI-UCSD
sdowdy@ucsd.edu
Dr. Angela Eggleston
Nature Publishing Group
a.eggleston@us.nature.com
Dr. Akiko Eguchi
UCSD
aeguchi@ucsd.edu
Dr. Andrew Ellington
University of Texas at Austin
andy.ellington@mail.utexas.edu
Mr. Melvin Evers
Leiden University Medical Center
m.m.evers@lumc.nl
Dr. Diane Frank
AVI BioPharma
dfrank@avibio.com
Dr. Rajesh Gaur
Beckman Research Institute of the City of 
Hope
rajeshgaur@usa.com
Dr. Richard Geary
Isis Pharmaceuticals Inc.
rgeary@isiph.com
Dr. Paloma Giangrande
University of Iowa
paloma-giangrande@uiowa.edu
Dr. Peter Glazer
Yale University School of Medicine
peter.glazer@yale.edu
Mr. Michael Grote
Roche Kulmbach GmbH
michael.grote@roche.com
Dr. Samuel Gunderson
Rutgers University
gunderson@biology.rutgers.edu
Dr. Peter Hare
Nature Publishing Group
p.hare@us.nature.com
Dr. Benjamin Heuberger
Howard Hughes Medical Institute/MGH
heuberger@molbio.mgh.harvard.edu
Dr. Stephen Hughes
Glaxo Smith Kline
sah15453@gsk.com
Dr. Norihiro Ikemoto
Merck
norihiro_ikemoto@merck.com
Dr. Patrick Iversen
AVI Biopharma
piversen@avibio.com
Ms. Yuanyuan Jin
Thomas Jefferson University
yuanyuan.jin@jefferson.edu
Dr. Rudy Juliano
University of North Carolina
arjay@med.unc.edu
Ms. Saba Khaliq
University of the punjab, Lahore
sabahat711@yahoo.com
Dr. Bernard Khoo
UCL Medical School
b.khoo@ucl.ac.uk
Dr. Anastasia Khvorova
RXi Pharmaceuticals
tmcgrillen@rxipharma.com
Mr. Jason Killough
Archemix Corp.
jkillough@archemix.com
Dr. Randall Kincaid
Dept of Defense
randall.kincaid@dtra.mil
Prof. Ryszard Kole
AVI BioPharma
rkole@avibio.com
Dr. Edyta Koscianska
Institute of Bioorganic Chemistry, PAS
edytak@ibch.poznan.pl
Dr. Adrian Krainer
Cold Spring Harbor Laboratory
krainer@cshl.org
Dr. Arthur Krieg
Pfizer
arthur.krieg@pfizer.com
Dr. Nelly Kuklin
Merck
nelly_kuklin@merck.com
Ms. Johanna Lee
Baylor College of Medicine
jelee@bcm.edu
Prof. Tsai-Kun Li
College of Medicine, National Taiwan 
University
tsaikunli@ntu.edu.tw
 Loreen Lofts
USAMRIID
loreen.lofts@us.army.mil
Dr. Muthiah Manoharan
Alnylam Pharmaceuticals
mmanoharan@alnylam.com
Dr. Steve Mao
Cold Spring Harbor Laboratory
ymao@cshl.edu
Dr. Xin Ming
UNC-Chapel Hill
xming@email.unc.edu
Ms. Martiene Moester
Leiden University Medical Centre
m.j.c.moester@lumc.nl
Dr. Francesco Muntoni
UCL Institute of Child Health
f.muntoni@ich.ucl.ac.uk
Dr. Osamu Nakagawa
The University of North Carolina at Chapel 
Hill
osamu_nakagawa@unc.edu
Dr. SubbaRao Nallagatla
Pennsylvania State University
sxn19@psu.edu
Dr. Marta Olejniczak
Institute of Bioorganic Chemistry, PAS
marbi@ibch.poznan.pl
Dr. Henrik Orum
Santaris Pharma
HOE@santaris.com
Ms. Amber Paschal
PhaseRx Pharma
amber@phaserx.com
Dr. Pamela Pavco
RXI Pharmaceuticals
tmcgrillen@rxipharma.com
Dr. Thoru Pederson
University of Massachusetts Medical School
thoru.pederson@umassmed.edu
Dr. Yi Pei
Merck & Co, Inc
yi_pei@merck.com
Dr. Shannon Pendergrast
Archemix Corporation
pendergrast@archemix.com
Dr. Jacob Ravn
Santaris Pharma A/S
jra@santaris.com
Dr. John Rossi
Beckman Research Institute
jrossi@coh.org
Mr. Peter Sazani
AVI BioPharma
psazani@avibio.com
Dr. Shaguna Seth
MDRNA Inc.
sseth@mdrnainc.com
Mr. David Sharon
University of Alberta
ds26@ualberta.ca
Dr. Stephen Shrewsbury
AVI Biopharma
sshrewsbury@avibio.com
Dr. Bruce Sullenger
Duke University
bruce.sullenger@duke.edu
Dr. Weikang Tao
Merck Research Laboratories
weikang_tao@merck.com
Dr. Charles Thornton
University of Rochester
charles_thornton@urmc.rochester.edu
Dr. Johannes Urban
Duke University
ju6@duke.edu
Dr. Judith Van Deutekom
Prosensa
j.vandeutekom@prosensa.nl
Dr. Gertjan Van Ommen
Leiden University Medical Center, Leiden 
NL
gjvo@lumc.nl
Dr. Willeke van Roon-Mom
Leiden University Medical Center
w.vanroon@lumc.nl
Ms. Anna Vilborg
Karolinska Institute
anna.vilborg@ki.se
Prof. Eric Wickstrom
Thomas Jefferson University
eric@tesla.jci.tju.edu
Ms. Daiying Xu
SUNY, UAlbany
dx658379@albany.edu
Ms. Ping Ye
Pfizer
ping.ye@pfizer.com
Dr. Sungsook Yu
National Cancer Center
sungsook@ncc.re.kr
Mr. Jonathan Zuckerman
Caltech
jezucker@caltech.edu
VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, west wing, lower level 
 PIN#:  Press 64315 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
